Once-daily formulation of dexmethylphenidate achieved primary endpoint (p 0.001) with consistent symptom relief up to 12 hours post-dose KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate's technology will let ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果